These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34384016)

  • 1. Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    Park B; Kim D; Kim J; Lee BY; Yoon J; Kim SW
    Cancer Res Treat; 2022 Apr; 54(2):375-382. PubMed ID: 34384016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
    Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
    Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
    JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
    Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
    Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
    Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
    J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
    Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
    Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
    Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    Loizzi V; Cicinelli E; Del Vecchio V; Arezzo F; Deromemaj X; Kardhashi A; Paradiso A; Legge F; Natalicchio MI; Resta L; Resta N; Loconte DC; Cormio G
    Acta Biomed; 2022 Aug; 93(4):e2022051. PubMed ID: 36043985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    Ladd MK; Peshkin BN; Senter L; Baldinger S; Isaacs C; Segal H; Philip S; Phillips C; Shane K; Martin A; Weinstein V; Pilarski R; Jeter J; Sweet K; Hatten B; Wurtmann EJ; Phippen S; Bro D; Schwartz MD
    Transl Behav Med; 2020 May; 10(2):337-346. PubMed ID: 30418620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
    Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan.
    Nomura H; Abe A; Fusegi A; Yoshimitsu T; Misaka S; Murakami A; Matsumoto T; Tsumura S; Kanno M; Aoki Y; Netsu S; Omi M; Tanigawa T; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Habano E; Arakawa H; Kaneko K; Ueki A; Haruyama Y; Inari H; Ueno T
    Sci Rep; 2023 Jan; 13(1):1018. PubMed ID: 36658289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
    Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
    Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
    Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.